硝呋泰-制霉菌素联合克林霉素-克霉唑治疗细菌性阴道病的疗效及安全性观察。随机对照临床试验

F. E. L. Hoz
{"title":"硝呋泰-制霉菌素联合克林霉素-克霉唑治疗细菌性阴道病的疗效及安全性观察。随机对照临床试验","authors":"F. E. L. Hoz","doi":"10.36811/ijrmsh.2021.110010","DOIUrl":null,"url":null,"abstract":"Introduction: Bacterial vaginosis (BV) is the most frequent gynecological infection in women of reproductive age, thus driving the search for effective and safe treatments.\n\nObjective: To compare the efficacy and safety of the combination nifuratel-nystatin and clindamycinclotrimazole, in the treatment of bacterial vaginosis.\n\nMaterials and Methods: Randomized controlled clinical trial in 147 single women (18 to 39 years old), non-pregnant and sexually active, with a diagnosis of BV according to the Amsel clinical criteria and the Nugent score; between 2016 and 2018. In a highly complex private clinic in Armenia, Colombia. Women were randomized into two groups: \"A\" (73 participants: nifuratel (500 mg) - nystatin (100,000 IU) and \"B\" (74 participants: clindamycin (100 mg) - clotrimazole (200 mg)); both groups were treated with vaginal ovules, \"A\" for six days and \"B\" for three days. All participants were followed-up for clinical and microbiological healing at 7 and 30 days, respectively, after completion of treatment, the STATA® 14.0 program was used.\n\nResults: The mean age of women was 28.35±5.79 years. The clinical cure rate with the nifuratelnystatin combination was 93.15%, and that of clindamycin-clotrimazole 97.29%, (p=0.123). The microbiological cure rate with the nifuratel-nystatin combination was 87.67%, and that of clindamycin-clotrimazole 93.24%, (p=0.102). Regarding safety, there were also no significant differences between the two groups (p=0.144); Mild adverse reactions were observed. Recurrence in group \"A\" was 12.32% compared to 6.75% in group \"B\" (p>0.05).\n\nConclusions: In this study, the combinations nifuratel (500 mg) -nystatin (100,000 IU) and clindamycin (100 mg)-clotrimazole (200 mg), reported that both are equally effective and safe options in the treatment of BV. It is necessary to evaluate the effect and safety of other combinations in order to implement timely interventions.\n\nKeywords: Vaginosis; Bacterial; Efficacy; Safety; Nifuratel; Nystatin; Clindamycin; Clotrimazole.","PeriodicalId":14247,"journal":{"name":"International Journal of Reproductive Medicine and Sexual Health","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Efficacy and safety of the combination nifuratel-nystatin and clindamycin-clotrimazole, in the treatment of bacterial vaginosis. Randomized controlled clinical trial\",\"authors\":\"F. E. L. Hoz\",\"doi\":\"10.36811/ijrmsh.2021.110010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Bacterial vaginosis (BV) is the most frequent gynecological infection in women of reproductive age, thus driving the search for effective and safe treatments.\\n\\nObjective: To compare the efficacy and safety of the combination nifuratel-nystatin and clindamycinclotrimazole, in the treatment of bacterial vaginosis.\\n\\nMaterials and Methods: Randomized controlled clinical trial in 147 single women (18 to 39 years old), non-pregnant and sexually active, with a diagnosis of BV according to the Amsel clinical criteria and the Nugent score; between 2016 and 2018. In a highly complex private clinic in Armenia, Colombia. Women were randomized into two groups: \\\"A\\\" (73 participants: nifuratel (500 mg) - nystatin (100,000 IU) and \\\"B\\\" (74 participants: clindamycin (100 mg) - clotrimazole (200 mg)); both groups were treated with vaginal ovules, \\\"A\\\" for six days and \\\"B\\\" for three days. All participants were followed-up for clinical and microbiological healing at 7 and 30 days, respectively, after completion of treatment, the STATA® 14.0 program was used.\\n\\nResults: The mean age of women was 28.35±5.79 years. The clinical cure rate with the nifuratelnystatin combination was 93.15%, and that of clindamycin-clotrimazole 97.29%, (p=0.123). The microbiological cure rate with the nifuratel-nystatin combination was 87.67%, and that of clindamycin-clotrimazole 93.24%, (p=0.102). Regarding safety, there were also no significant differences between the two groups (p=0.144); Mild adverse reactions were observed. Recurrence in group \\\"A\\\" was 12.32% compared to 6.75% in group \\\"B\\\" (p>0.05).\\n\\nConclusions: In this study, the combinations nifuratel (500 mg) -nystatin (100,000 IU) and clindamycin (100 mg)-clotrimazole (200 mg), reported that both are equally effective and safe options in the treatment of BV. It is necessary to evaluate the effect and safety of other combinations in order to implement timely interventions.\\n\\nKeywords: Vaginosis; Bacterial; Efficacy; Safety; Nifuratel; Nystatin; Clindamycin; Clotrimazole.\",\"PeriodicalId\":14247,\"journal\":{\"name\":\"International Journal of Reproductive Medicine and Sexual Health\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Reproductive Medicine and Sexual Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36811/ijrmsh.2021.110010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Reproductive Medicine and Sexual Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36811/ijrmsh.2021.110010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

细菌性阴道病(BV)是育龄妇女中最常见的妇科感染,因此促使人们寻找有效和安全的治疗方法。目的:比较尼夫拉特-制霉菌素与克林霉素联合治疗细菌性阴道病的疗效和安全性。材料与方法:随机对照临床试验147例,年龄18 ~ 39岁,未怀孕,性活跃,根据Amsel临床标准和Nugent评分诊断为BV的单身女性;在2016年到2018年之间。在哥伦比亚亚美尼亚一家非常复杂的私人诊所里。妇女被随机分为两组:“A”组(73名参与者:尼夫拉特(500毫克)-制霉菌素(100,000国际单位)和“B”组(74名参与者:克林霉素(100毫克)-克霉唑(200毫克));两组均接受阴道胚珠治疗,A组治疗6天,B组治疗3天。所有参与者分别在治疗完成后7天和30天随访临床和微生物愈合情况,使用STATA®14.0程序。结果:女性平均年龄28.35±5.79岁。硝伐他汀联合用药的临床治愈率为93.15%,克林霉素-氯曲霉唑联合用药的临床治愈率为97.29%,差异有统计学意义(p=0.123)。硝呋泰联合制霉菌素组微生物治愈率为87.67%,克林霉素联合克霉唑组为93.24%,差异有统计学意义(p=0.102)。在安全性方面,两组间也无显著差异(p=0.144);观察到轻微不良反应。A组复发率为12.32%,B组为6.75% (p < 0.05)。结论:在本研究中,尼夫拉特(500mg)-制霉菌素(100,000 IU)和克林霉素(100mg)-克霉唑(200mg)联合治疗细菌性肠炎是同样有效和安全的选择。为了及时实施干预措施,有必要评估其他联合用药的效果和安全性。关键词:阴道炎;细菌;功效;安全;Nifuratel;制霉菌素;克林霉素;克霉唑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy and safety of the combination nifuratel-nystatin and clindamycin-clotrimazole, in the treatment of bacterial vaginosis. Randomized controlled clinical trial
Introduction: Bacterial vaginosis (BV) is the most frequent gynecological infection in women of reproductive age, thus driving the search for effective and safe treatments. Objective: To compare the efficacy and safety of the combination nifuratel-nystatin and clindamycinclotrimazole, in the treatment of bacterial vaginosis. Materials and Methods: Randomized controlled clinical trial in 147 single women (18 to 39 years old), non-pregnant and sexually active, with a diagnosis of BV according to the Amsel clinical criteria and the Nugent score; between 2016 and 2018. In a highly complex private clinic in Armenia, Colombia. Women were randomized into two groups: "A" (73 participants: nifuratel (500 mg) - nystatin (100,000 IU) and "B" (74 participants: clindamycin (100 mg) - clotrimazole (200 mg)); both groups were treated with vaginal ovules, "A" for six days and "B" for three days. All participants were followed-up for clinical and microbiological healing at 7 and 30 days, respectively, after completion of treatment, the STATA® 14.0 program was used. Results: The mean age of women was 28.35±5.79 years. The clinical cure rate with the nifuratelnystatin combination was 93.15%, and that of clindamycin-clotrimazole 97.29%, (p=0.123). The microbiological cure rate with the nifuratel-nystatin combination was 87.67%, and that of clindamycin-clotrimazole 93.24%, (p=0.102). Regarding safety, there were also no significant differences between the two groups (p=0.144); Mild adverse reactions were observed. Recurrence in group "A" was 12.32% compared to 6.75% in group "B" (p>0.05). Conclusions: In this study, the combinations nifuratel (500 mg) -nystatin (100,000 IU) and clindamycin (100 mg)-clotrimazole (200 mg), reported that both are equally effective and safe options in the treatment of BV. It is necessary to evaluate the effect and safety of other combinations in order to implement timely interventions. Keywords: Vaginosis; Bacterial; Efficacy; Safety; Nifuratel; Nystatin; Clindamycin; Clotrimazole.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信